Among 347,468 individuals who had lived with persistent pain for over 3 months, clinical symptoms of depression and anxiety ...
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback